Last reviewed · How we verify
Efficacy and Safety of Thrombolytic Therapy With Half Dose Alteplase, Added to Standard Anticoagulation Therapy With Heparine, in Patients With Moderate Pulmonary Embolism: a Prospective, Randomized, Open Label,Controlled Trial (MONALYSE)
The primary aim of this study is to evaluate whether mid dose (safe dose) of Alteplase in addition to standard treatment with heparin (LMWH) in patients with pulmonary embolism (PE) at intermediate risk, it is effective to reduce: * right ventricular dysfunction * pulmonary hypertension 24 hours and 7 days after the treatment * PE recurrence to 7days and 30 days after the treatment without increasing the incidence of bleeding intra-extracranial
Details
| Lead sponsor | Azienda U.S.L. 1 di Massa e Carrara |
|---|---|
| Phase | Phase 3 |
| Status | WITHDRAWN |
| Start date | 2016-03 |
| Completion | 2016-03 |
Conditions
- Pulmonary Embolism
Interventions
- Alteplase
Primary outcomes
- Pulmonary hypertension reduction (systolic pulmonary pressure greater or equal to 30 mm Hg) — 24 hour
Pulmonary hypertension reduction documented on echocardiography